야마토5게임기 79.rsk396.top 바로가기 온라인삼국지 오토, 릴게임환전

파친코게임다운로드 60.rsk396.top 올쌈바

바다이야기디시 31.rsk396.top 무료신천지게임

바다이야기 시즌7 9.rsk396.top 황금성포커

오션파라다이스 릴게임 67.rsk396.top 릴게임종류

최신인터넷게임 14.rsk396.top 릴게임 사이트

바다이야기 꽁머니 환전 윈윈 76.rsk396.top 모바알바다이야기

바다이야기게임하기 70.rsk396.top 최신바다게임

온라인야마토게임 19.rsk396.top 파칭코 어플

황금성배당 78.rsk396.top 바다신게임

슬롯머신 4.rsk396.top 바다이야기 무료게임 다운로드

바로가기 go !! 바로가기 go !!

10원야 마토 바다이야기게임장 황금성갈갈이 야마토게임하기 황금성게임다운로드후기 릴게임 백경게임공략방법 바다이야기 꽁머니 환전 바다이야기 확률 온라인야마토2 일본빠찡코 릴게임사이트 릴게임다빈치 오션파라 다이스다운 온라인릴게임 성인릴게임 바다이야기 5만 오션파라다이스게임사이트 릴게임신천지사이트 도그하우스 하는법 올벳매거진 오션파라다이스동영상 바다이야기사이트먹튀 jQuery 슬롯 머신 야마토게임공략 법 알라딘릴게임오락실 야마토게임 손오공게임 바둑이라이브 빠친코게임 신천지게임하는곳 황금성동영상 황금성검증 인터넷야마토주소 온라인 슬롯 공략 야마토하는법 캡틴프라이드게임 황금성 일본 야마토 게임 우주전함야마토2199 야마토게임동영상 카카오야마토먹튀 카지노릴게임 최신게임 릴게임바다이야기 바다이야기 도박 릴게임횡금성 Pg 소프트 무료 체험 온라인황금성주소 릴게임손오공하는법 꽁머니 릴게임추천 알라딘사이트 바다이야기 노무현 바다이야기 도박 손오공 온라인 게임 다빈치릴게임다운로드 온라인신천지게임 릴게임 5만 바다이야기pc 릴게임 종류 슬롯 추천 디시 슬롯 릴게임야마토 바다이야기 프로그램 바다이야기먹튀돈받기 오션파라 다이스7 바다이야기황금고래 바다이야기릴게임 릴게임팡게임 바다이야기 슬롯 사이트추천 온라인 슬롯 게임 추천 모바일바다이야기 알라딘예시 골드몽 황금성게임공략방법 릴게임다운 온라인릴게임 빠친코게임 바다이야기게임하는곳 온라인슬롯 전략 릴게임 먹튀보증 바다이야기 게임 다운로드 무료게임 골드몽먹튀 온라인파칭코 백경 야마토예시 바다이야기7 바다이야기 다운로드 슬롯머신무료 알라딘예시 모바일파칭코 온라인 슬롯 머신 게임 최신인터넷게임 강원랜드 슬롯 잘 터지는 기계 파칭코 어플 체리마스터 릴게임 바다게임 다빈치게임 먹튀 피해 복구 모바일릴게임접속하기 신천기릴게임 바다이야기5 슬롯 무료 사이트 슬롯머신 이기는 방법 파칭코게임 씨엔조이게임 야마토게임하기 온라인 손오공 릴게임 슬롯 무료체험 신야마토 알라딘꽁머니 알라딘게임잭팟 체리마스터 확률 릴게임동영상 오션파라다이스 릴게임 체리마스터 슬롯게임 하는법 야마토카지노 바다이야기시즌5 바다이야기넥슨 바다이야기고래 모바일릴게임사이트 This article was released as Pharm Edaily Premium Content on September 21, 2025, at 2:18 PM.


[Shin-Min Joon, Edaily Reporter] On the 19th shares of Korean biopharmaceutical companies Olix and Hanmi Pharmaceutical both developing new drugs for Metabolic Dysfunction-Associated Steatohepatitis (MASH) posted notable gains.
The surge was driven by optimism sur 제2금융 금리 rounding the MASH market after global pharma giant Roche announced plans to acquire a MASH drug developer for approximately 5 trillion won. Additionally Ildong Pharmaceutical’s stock rose after a prev 전세보증금 압류 iously paywalled article from Pharmedaily regarding its obesity drug trial was made publicly available.



Olix stock trend on Sep 19. (Image=MP Doctor)
청소년신용불량


Roche to Acquire MASH Drug Developer for 5 Trillion Won

According to KG Zeroin’s MP DOCTOR (formerly Market Point), shares of Olix rose 1 예금이율계산기 8.46% on the day to 100,100 won. The surge followed news that Roche will acquire 89Bio, a U.S.-based MASH drug developer, for up to $3.5 billion (approximately 5 trillion won), with the deal expected 영세민전세자금대출서류 to close in Q4 of this year. After the acquisition, 89Bio will be integrated into Roche’s pharmaceutical division.
89Bio is currently conducting Phase 3 trials for its MASH drug candidate, pegozafermin. MASH is a chronic liver disease associated with obesity and metabolic disorders, potentially progressing to fibrosis, cirrhosis, and liver-related mortality. In 2023, 89Bio’s Phase 2b trial showed promising results in fibrosis improvement. The company is expected to release Phase 3 results in the first half of 2027.
Olix previously licensed its own MASH and obesity treatment candidate, OLX702A, to Eli Lilly in February for $630 million (approx. 911.7 billion won at the time). OLX702A is based on promising genetic targets identified through genome-wide association studies (GWAS), a method for finding disease-related genes by analyzing genomic variations in large populations.
Preclinical studies demonstrated that OLX702A not only showed efficacy in MASH and liver fibrosis, but also in other cardiovascular and metabolic diseases. Currently, a Phase 1 trial is ongoing in Australia, with the Clinical Study Report (CSR) expected in the first half of next year.
In addition to its MASH drug, Olix is also developing OLX301A for wet age-related macular degeneration and OLX104C for male-pattern hair loss. OLX301A is undergoing Phase 1 trials, with a CSR expected within the year. OLX104C completed its Phase 1a trial in January.
An Olix representative stated, “Roche’s acquisition of 89Bio has increased expectations for the MASH treatment market.”
Hanmi Pharmaceutical’s Triple Agonist Draws Attention
Shares of Hanmi Pharmaceutical also jumped 8.42% to 360,500 won. The rally appears to be driven by investor optimism over the company’s MASH drug pipeline. Hanmi currently has two MASH drug candidates under development. One of them, efocipegtrutide, is in Phase 2b trials in both Korea and the United States.
Efocipegtrutide is a long-acting triple agonist that targets glucagon, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1), enhanced through Hanmi’s LAPSCOVERY platform. It has received Fast Track designation from the U.S. Food and Drug Administration (FDA) based on promising results in preclinical and early-phase trials.
Hanmi also out licensed epinopegdutide to Merck (MSD) in 2020, which is now in Phase 2 trials. Results are expected by year end. Epinopegdutide is a long acting dual agonist targeting GLP-1 and glucagon receptors.
With obesity and diabetes on the rise, the global MASH drug market is expected to expand. Market research firm DataM Intelligence forecasts that the MASH treatment market will grow from $7.8 billion (approx. 11 trillion won) in 2024 to $31.8 billion (approx. 44 trillion won) by 2033.
A Hanmi spokesperson said, “Hanmi is exploring innovative drug development across various therapeutic areas, not limited to specific diseases, and expanding its pipeline accordingly.”
Ildong’s Oral Obesity Drug Raises Hopes
Ildong Pharmaceutical shares rose 7.90% to 30,050 won, driven by anticipation over the upcoming topline results of its Phase 1 trial for the oral obesity drug ID110521156. Among Korean companies Ildong is leading in the clinical development of oral obesity drugs. Interim results have already shown competitive weight loss efficacy compared to global players.
A Pharmedaily article released on the day stated that the key lies in high dose data though even low doses have already proven effective. The article suggested that global benchmark results may be attainable.
ID110521156 achieved an average weight loss of 6.9% after four weeks in its Phase 1 interim results. The drug outperformed rivals such as Roche and Viking Therapeutics across both low and high dose groups.
Unlike injectable GLP-1 peptide drugs like Wegovy or Mounjaro ID110521156 is a small molecule GLP-1 agonist enabling better gastrointestinal absorption and higher success potential as an oral formulation.
The drug also showed only mild gastrointestinal side effects. In comparison Viking Therapeutics had a treatment discontinuation rate of 20% due to adverse effects. Ildong is expected to present topline data from the trial during a company presentation (NDR) for institutional investors on the 29th.
Ildong stated in a recent disclosure “We will hold an investor presentation on the 29th for institutional investors and analysts to enhance understanding and boost corporate value” adding “Topline results from the Phase 1 trial of ID110521156 will be revealed during the session.”
신민준 (adonis@edaily.co.kr)